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Abstract In this review, we present a critical review of the existing literature reflecting the results of explantation of
silicone breast implants in patients with silicone-related complaints and/or autoimmune diseases. A literature search
was performed to discuss the following issues: which clinical manifestations and autoimmune diseases improve after
explantation, and what is the course of these complaints after explantation. Next, we reviewed studies in which the
effect of explantation on laboratory findings observed in patients with silicone breast implants was studied, and lastly,
we reviewed studies that described the effect of reconstruction of the breast with a new implant or autologous tissue
after explantation. We calculated from the literature that explantation of the silicone breast improved silicone-related
complaints in 75 % of the patients (469 of 622). In patients with autoimmune diseases, however, improvement was
only infrequently observed without additional therapy with immunosuppressive therapy, i.e., in 16 % of the patients (3
of 18). The effect of explantation did not influence autoantibody testing such as ANA. We discuss several possibilities
which could clarify why patients improve after explantation. Firstly, the inflammatory response could be reduced after
explantation. Secondly, explantation of the implants may remove a nociceptive stimulus, which may be the causative
factor for many complaints. Options for reconstruction of the explanted breast are autologous tissue and/or water-/
hydrocellulose-filled breast implant. Unfortunately, in very few studies attention was paid to reconstructive possibil-
ities. Therefore, no adequate conclusion regarding this issue could be drawn. In conclusion, explantation is useful for
improvement of silicone-related complaints in 75 % of the patients, whereas in patients who developed autoimmune
diseases improvement is only observed when explantation is combined with immunosuppressive therapy. In a patient
with silicone-related complaints in which explantation is considered, the patient should be counseled for the different
options of reconstruction after explantation.
Keywords Silicone breast implants  Silicone (adverse effect)  Explantation  Removal
Introduction
Since the introduction of silicone breast implants in the
early 1960s, it has been postulated that patients may
develop complaints related to silicone breast implants.
Hence at present, there is still controversy whether breast
implants are safe [1, 2].
Patients with implants may develop nonspecific com-
plaints such as arthralgia, myalgia and fatigue. In the past
years, these complaints in patients with silicone breast
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implants have been named differently: human adjuvant
disease or adjuvant breast disease, silicone-related symp-
tom complex, siliconosis and more recently ASIA syn-
drome due to silicone implant incompatibility syndrome
(SIIS) [3–11]. In these patients, it is postulated that silicone
act as an adjuvant to the immune system, resulting in
inflammation, autoimmune diseases, immunodeficiencies
and/or allergies [10]. In search of an effective therapy for
these patients, it is the current practice to advise patients to
undergo explantation of their implants. In this paper, we
review the existing literature addressing the effectiveness
of implant removal as treatment for patients with com-




Weperformed a comprehensive literature search in PubMed,
MEDLINE, EMBASE and the Cochrane Central Register of
Controlled Trials, and the Cochrane Database of Systematic
Reviews through the first quarter of 2016. Additional cita-
tions were solicited from references in selected articles. The
searches combined the following terms: ‘Breast implants
[Mesh],’ ‘Silicone, adverse effect [Mesh],’ for the period
between January 1960 and the present time. An additional
search to cross-reference the outcome of the previous search
was performed with the terms ‘removal,’ ‘explantation’ and
‘Device Removal Mesh.’
We included studies discussing patients with breast
implants (silicone- or saline-filled) who reported or presented
with silicone-related complaints (Table 1) after insertion of
the breast implants and who underwent explantation of the
breast implant [4, 6–9]. Studies of all type were included,
meaning case reports, case series, case–control studies and
descriptive cohort studies.We excluded studies that described
explantation of breast implants that was performed because
the implants were ruptured and/or were leaking and no
description of silicone-related complaintswasmentioned.We
excluded also studies focussing on malignancies of the breast
after silicone breast implantation. Also, studies focussing on
silicone oil/gel injections were excluded.
We report on: (1) whether improvement of several sil-
icone-related complaints (including autoimmune diseases)
after explantation (Table 1) occurred; (2) what the course
of improvement of complaints is after explantation; (3)
what the effect of explantation is on laboratory findings; (4)
whether patients underwent reconstruction of the breast
after explantation or not.
Study extraction and assessment
Data from each included study were extracted. Extracted
data included study type, participants, implant characteris-
tics (if available), silicone-related complaints (Table 1),
laboratory findings (if available), explantation, status of
silicone-related complaints/autoimmune disease after
explantation, status of laboratory findings after explantation
(if available), course of disease/symptoms after explanta-
tion, reconstruction of explanted breast (if available).
The literature search yielded 720 citations. Firstly, titles
and abstracts were read. On the basis of titles and abstracts,
45 publications were provisionally accepted for review.
After screening of the full text, 17 studies met eligibility
criteria. Additionally, 6 studies were selected based on
references in these 17 studies that also met eligibility cri-
teria and were therefore retrieved and used as well (Fig. 1).
Of the 23 included studies, 10 were case reports/case series
(Table 2) and 13 studies were cohort studies (Table 3).
Results
Improvement of complaints after explantation: case
reports
Teuber et al. described a 45-year-old woman who pre-
sented with Raynaud’s phenomenon, myalgia, pyrexia,
malaise, cutaneous lesions, uveitis, enlarged lymph nodes
and shortness of breath, which developed 7 years after
cosmetic mamma augmentation. A X-ray of the chest
showed bilateral hilar lymphadenopathy and a trans-
bronchial biopsy revealed noncaseating granulomas con-
sistent with sarcoidosis. The course of the sarcoidosis was
progressive and only minimal responsive to prednisone
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(minimal improvement in pulmonary, ocular and joint
symptoms). However, cutaneous sarcoidosis and enlarged
lymph nodes resolved after explantation, whereas symp-
toms and clinical condition improved dramatically as well
[12].
Kivity et al. presented a patient who developed myalgias
and morphea after breast augmentation with silicone breast
implants. Due to tightening of the skin around the implants
and significant discomfort, the implants were surgically
removed. The clinical symptoms (myalgia, morphea) did
not improve after implant removal, whereas treatment with
1 mg/kg prednisone resulted in some improvement [13].
Chan et al. described a patient with arthralgias and
fatigue, which developed after mamma augmentation
with silicone breast implants 7 years earlier. Laboratory
screening showed increased inflammatory markers, such
as elevated sedimentation rate, positive ANA and IgG
anti-cardiolipin antibodies. A diagnosis of an unspeci-
fied inflammatory disease was made, and treatment with
methotrexate and steroids was started. Ultrasound of the
breast showed a ruptured left breast implant. The
patient chooses to replace the breast implants by new
silicone gel-filled implants. Soon after surgery, she
developed a rash. Subsequently, her breast implants
were removed. 10 weeks later, the methotrexate and
prednisolone could be stopped and the patient showed
complete resolution of her symptoms and the inflam-
matory response [14].
Citations retrieved from MEDLINE,











- No outcome of interest N = 16
- Cross sectional studies N=2
- Included only patients with specific symptoms not
mentioned in table1 (capsular contracture, rupture of
implant) N= 5












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nesher et al. presented a patient with a silicone breast
implant placed for reconstruction after a mastectomy. After
implant rupture a revision with a new silicone implant was
performed and subsequently, the patient developed fatigue,
arthralgia, myalgia, dry eyes, cognitive impairment, inter-
mittent abdominal pain, attacks of fainting, weight loss,
headaches and hand paresthesias [5]. An MRI showed
enlarged supra-clavicular lymph nodes possibly due to
silicone granuloma and enhancement of the chest wall after
gadolinium injection. After explantation, the fibromyalgia-
like symptoms did not improve, whereas generalized
weakness, fatigue and insomnia also persisted.
Kappel et al. described three sisters with a BRCA-1 gen
mutation who underwent preventive mastectomy and
reconstruction with silicone breast implants. All three
women developed fatigue, arthralgias, myalgias and sleep
disturbances within a period of four years after implanta-
tion [15]. All complaints improved as evaluated 2.5 years
after explantation of the implants.
Jara et al. presented a case report and discussed three
other patients who developed Still’s disease after silicone
breast implantation [16–19]. All four patients underwent
implant removal and experienced improvement. However,
all patients received additional therapy such as steroids,
intravenous immunoglobulins, azathioprine or methotrex-
ate. Three of the four patients remained steroid dependent
during long-term follow-up.
Levy et al. presented two cases with silicone breast
implants and systemic sclerosis who underwent explantation
[20]. Case 1 was a patient who underwent bilateral mamma
reconstruction with silicone breast implants. 14 years later,
she developed Raynaud’s phenomenon, heartburn and
swelling of fingers and toes, telangiectasia and fibrotic skin
changes. Laboratory screening showed ANA and anti-ScL-
70 autoantibodies. She underwent removal of the implants.
Rupture occurred during removal and silicones entered into
the blood stream. Several months later, she developed
extreme dyspnea, severe restrictive lung disease with low
CO diffusing capacity and interstitial lung disease. She died
two years after implant removal from progressive systemic
sclerosis. Case 2 comprises a 52-year-old patient who
underwent mastectomy and 3 years later insertion of a sili-
cone breast implant. 7 years later, she developed arthralgias,
Raynaud’s phenomenon, sclerodactyly and telangiectasia.
Laboratory screening showed increased CRP and positive
ANA. Due to gradual hardening of the implant associated
with pain, the patient opted for replacement. Several months
later, the replaced implant ruptured and was removed with-
out further replacement. Clinical symptoms did not improve
after explantation.
Granel et al. presented a 53-year-old woman who
underwent mamma reconstruction with silicone breast
implants [21]. Localized morphea occured after 1 year.
The implant was replaced by a saline-filled implant with a
polyurethane-covered silicone capsule. Disease progression
occurred with persisting morphea without signs of systemic
sclerosis.
Meier et al. described two HLA identical sisters who
both received silicone breast implants and subsequently
developed polyarthritis and neurological symptoms [22].
After removal of the implants, the rheumatic as well as
neurological symptoms improved dramatically in both
patients. One patient achieved complete remission. The
other patient had mild residual symptoms.
Homsi et al. presented a 49-year-old woman who pre-
sented with necrotizing vasculitis following silicone breast
implants because of congenital breast asymmetry. The
patients suffered from digital ischemia, right leg paresis
and inflammation of the inferior part of the left breast. Due
to cutaneous necrosis of the breast, the patient underwent
capsulotomy and removal of the implant. Histopathological
examination showed necrotizing arteritis. Treatment with
high dose prednisone and mycophenolate mofetil was ini-
tiated, and after one year of follow-up, a persistent remis-
sion was observed [23].
Shoaib et al. described two patients with human adjuvant
disease due to SBIwho underwent implant removal [24]. The
first patient presented with arthralgia, fatigue and neuro-
logical manifestations six years after (cosmetic) augmenta-
tion. She was diagnosed with atypical multiple sclerosis.
Explantation did not result in improvement, whereas intra-
venous cyclophosphamide and immunoglobulins did. The
second patient presented two years after augmentation with
the same clinical manifestations as patient 1 and additional
symptoms such as myalgia, memory and concentration
problems, sicca complaints, irritable bowel syndrome and
Raynaud’s phenomena. An MRI showed demyelinisation
and she was diagnosed with atypical multiple sclerosis. She
underwent explantation 3 years after the first symptoms and
improvement wasminimal, i.e., only observed in diminished
Raynaud’s phenomenon.
Case reports are summarized in Table 2.
Improvement of complaints after explantation: Case
series
Vasey et al. presented 50 patients with silicone breast
implants with findings such as fatigue, myalgias, arthral-
gias and lymphadenopathy [25]. Thirty-three women
underwent implant removal and 17 did not undergo implant
removal. During an observation period of 14 months, the
complaints did not change in the 17 patients without
explantation, whereas in the patients with explantation, 24
women improved (no symptoms anymore), 8 did not
change, and in only one patient, symptoms worsened after
an average follow-up of 22 months.
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Aziz et al. prospectively followed 95 women who had
silicone gel-filled breast implants and rheumatologic
symptoms (arthralgia, myalgia) and fatigue and found that
the symptoms improved in 42 (97 %) of the 43 women
who had their breast implants removed [26]. In contrast,
rheumatologic symptoms worsened in 50 (96 %) of 52
women who did not have their implants removed.
Thomas et al. presented 25 patients who underwent
implant removal because of arthralgias, sicca complaints
and hypesthesia [27]. Improvement in patient-reported
symptoms and signs occurred over the course of months
postoperatively in all patients.
Kappel et al. presented a study in which they compared
a group of patients with silicone breast implants with
complaints such as fatigue, myalgias, arthralgias, memory
and sleep disturbances who underwent removal, capsulec-
tomy and subsequently insertion of a hydrocellulose-filled
implant (n = 22) to a group of patients with silicone breast
implants with similar symptoms as the patients in the first
group who underwent removal and insertion of a the
hydrocellulose-filled implant, but no capsulotomy (n = 13)
[28]. A questionnaire examining the presence of symp-
toms pre-operatively and post-operatively was filled in by
patients of both groups. In both symptomatic groups, a
significant decline of the presence of symptoms was
observed. Only arthralgias, however, did not improve in the
patients who underwent explantation without capsulec-
tomy. Importantly, improvement appeared to be more
pronounced when an additional capsulectomy was
performed.
Walden et al. prospectively studied the outcome of
explantation in a group of 22 patients with silicone implants
with complains such as arthralgias using a questionnaire for
health status and compared the results to a group of patients
who underwent a cholecystectomy (n = 20) [29]. In the
explantation group, self-reported health rating scores
improved from 2.64 to 4.89, but did not change in the
cholecystectomy group (7.57 to 8.07). Unfortunately, the
exact number of patients who experienced improvement is
not mentioned in this study.
Rohrich et al. prospectively assessed the efficacy of
explantation of silicone breast implants in 38 women with
complaints such as arthralgia and fatigue. Self-evaluation of
the health status was done preoperatively and 6 weeks and
6 months postoperatively. In addition, the general practi-
tioner evaluated the health status of the patients [30]. After
explantation, patients showed an improvement in measure-
ments of arthralgia and pain, as well as an increase in vitality,
mental health and body area satisfaction when compared
with preoperative measurements. Unfortunately, authors do
not state what number of patients experienced improvement.
Svahn et al. retrospectively studied health improvement
following removal of silicone gel-filled breast implants in
63 female patients [31]. Quality of life was assessed by a
questionnaire in which physical and cognitive function was
studied. Improvement in symptoms occurred in 49 of the
63 (78 %) patients regarding quality of life.
In the largest study to date, Mehmed et al. described
explantation in 240 women who presented with symptoms
such as chronic fatigue, memory loss, arthralgia, dyspha-
gia, depression, altered sleep patterns, hair loss, skin
rashes, headaches, flu-like symptoms and atypical multiple
sclerosis [32]. After explantation, 74 % of the patients
reported that they felt much better. Especially, dry eyes and
flu-like symptoms improved quickly. MS-like symptoms,
however, did not improve.
Godfrey et al. presented 37 patients with silicone breast
implants and complaints such as fatigue, myalgia, arthral-
gia, hair loss, paresthesia, Raynaud’s phenomenon, dry
eyes/mouth, dizziness and headache who underwent
replacement of breast implants [33]. Postoperatively, a
major improvement in symptoms was observed in 89 % of
patients. However, at 6 months postoperatively, symptoms
returned in most patients leaving only 32 % of the patients
asymptomatic during longer follow-up.
Peters et al. evaluated the outcome of removal of breast
implants in 75 symptomatic patients after extensive eval-
uation preoperatively [34]. Patients had complaints such as
arthralgia, myalgia, fatigue, gastrointestinal symptoms,
rashes, memory loss, sleep disturbances and breast pain.
2.7 years after explantation, 56 patients stated that their
quality of life had improved. Six of 75 patients had a
proven autoimmune disease (see Table 3). After follow-up,
none of these patients had shown any improvement in
clinical status or autoantibody levels.
Recently, Maijers et al. described a cohort of 80 patients
presenting with complaints such as fatigue, arthralgias,
myalgias, morning stiffness, night sweats, cognitive
impairment, dermatological symptoms and/or alopecia.
Fifty-two women underwent explantation. Thirty-six
women reported a significant decrease in the symptoms, of
which nine patients stated that they were completely
without complaints [35]. Eleven patients had an autoim-
mune disease such as Sjo¨gren’s syndrome or systemic
sclerosis. Unfortunately, it is not described whether these
patients did improve after explantation as well.
Case series are summarized in Table 3.
Effect of explantation on laboratory findings
Kivity et al. presented a patient with morphea undergoing
explantation of the breast implant. ANA was found to be
positive before removal [13]. 4 weeks after removal, ANA
were still present.
Also in the case that was reported by Jara et al., positive
ANA were found before and after implant removal [16].
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Levy et al. [20] reported a case with positive ANA.
After explantation, ANA remained strongly positive, and
anti-centromere antibodies and anti-dsDNA became
detectable.
In the study by Kappel et al. [28], three sisters under-
went explantation because of complaints. After explanta-
tion, IgG levels increased, whereas ANA remained positive
in these patients.
Peters et al. presented 5 patients with autoimmune dis-
eases and autoantibodies. After explantation (2.7 years)
autoantibodies persisted.
Campbell et al. presented a study in which the NK cell
function of 40 symptomatic patients with silicone breast
implants was evaluated before and after explantation [36].
After explantation, NK activity increased in 50 % of the
patients, whereas NK activity decreased in 26 % of the
patients and was unchanged in 24 %. Unfortunately, no
control group was studied to compare NK activity during
follow-up in healthy controls.
Effect of reconstruction after explantation
Few data are available with respect to the effect of
reconstruction after explantation.
Granel et al. present a 53-year-old woman with morphea
who underwent replacement of a silicone implant by a
saline-filled implant with a polyurethane capsule. Disease
progression occurred [21].
Kappel et al. describe explantation of silicone breast
implants in three symptomatic sisters and subsequently
replacement of hydrocellulose-filled implants [15]. Full
recovery did occur.
In another study by Kappel et al. [28], patients under-
went explantation of the silicone implant (with or without
capsulectomy) and immediate reconstruction with a
hydrocellulose-filled implant. Significant improvement in
symptoms did occur in these patients as well (N = 35).
Godfrey et al. present 37 patients who underwent replace-
ment of breast implants due to systemic complaints and sub-
sequently reconstructionwith autologous tissue (TRAMflap or
latissimus dorsi flap) [33]. At 6 months postoperatively, only
32.4 % of the patients remained free of symptoms.
Summary
Silicone-related complaints
In this review, we have described 11 case reports with a
total of 19 patients who underwent explantation [12–24]. In
these case reports, 12 of 19 patients (63 %) experienced
improvement of their silicone-related complaints after
explantation. Two of 17 patients experienced disease pro-
gression (12 %).
In the case series, we have 12 case series with a total of
703 patients who underwent explantation [25–36].
For 603 patients, it was well described whether clinical
status improved after explantation [25–28, 31–35]. Of 603
patients, 457 (76 %) experienced improvement of silicone-
related complaints after explantation. In one of 703
patients, evident disease progression after explanation was
reported.
In total (case reports ? case series), this implies that
469 of 622 patients (75 %) experienced improvement of
silicone-related complaints after explantation.
Autoimmune diseases
If we only assess the improvement in autoimmune diseases
after explantation, we see that in the case reports 10 of 12
patients with an autoimmune disease experienced some
improvement after explantation [12, 16–19, 22–24]. How-
ever, 7 of 10 patients who improved after explantation also
received immunosuppressive or immunomodulatory ther-
apy before, during or after implant removal. In the case
series, only one author, Peters [33], closely described the
presence of patients with an autoimmune disease in his
cohort and whether these patients improved after explan-
tation. None of the 6 patients with well-defined autoim-
mune disease improved after explantation. In total, this
implies that only 3 of 18 patients (16 %) with a well-de-
fined autoimmune disease did improve after explantation
without additional therapy. Furthermore, 7 of 18 patients
(39 %) with autoimmune diseases improved after explan-
tation in combination with adjuvant immunosuppressive
therapy.
Discussion
Whether silicone can elicit an inflammatory or autoimmune
response has been subject of debate since the introduction
of silicone breast implants. Up until the present, there is
still no conclusive evidence that proves whether silicone
implants are safe or unsafe. Furthermore, the exact preva-
lence of complaints in patients with silicone breast
implants is unknown [1]. Several studies implicate that
there is no increased risk to develop autoimmune diseases
after silicone breast implant insertion [2]. Therefore, the
FDA lifted the ban on these implants in 2004. Recently, it
has been suggested that the methodological designs of the
studies that influenced this decision were not correct and
that more research, especially in larger prospective cohorts,
is needed [3]. In light of the recent developments, e.g., the
uproar concerning the PIP and Silimed prosthesis, the
description of ASIA and breast implant-associated
anaplastic large cell lymphoma (BIA-ALCL) [4, 37], we
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agree that more attention should be paid to silicone-related
problems. Fortunately, this is already occurring as can be
seen by the representation of the articles that were included
in this review. After a first wave of articles in the 1990s, a
second wave of articles appeared during recent years.
Whether epidemiological studies do or do not demon-
strate an increase in autoimmune diseases is, however, less
relevant when one realizes that there are patients who
present with complaints that might be attributed to silicone
breast implants and that explantation of the implants is an
important treatment strategy to resolve these complaints.
In this review, we have therefore investigated the
effectivity of explantation of the silicone breast implant in
improving complaints. We found that explantation of the
silicone breast implant improved silicone-related com-
plaints in approximately 75 % of the patients (469 of 622).
Autoimmune diseases improved in approximately 56 % of
the patients (10 of 18); however, explantation had to be
combined with immunosuppressive therapy in most of
these patients.
There are several possibilities why patients improve
after explantation. Two possibilities that are not mutually
exclusive may clarify why explantation of breast implants
may result in improvement in symptoms: (1) explantation
of the silicone breast implant results in reduction in the
(auto-)immune response, (2) explantation of the silicone
breast implant results in reduction in nociceptive signals.
Reduction in the immune response
In different experimental models, it has been demonstrated
that silicone can induce an autoimmune or inflammatory
response [38–40]. Moreover, in humans, adjacent to the
periprosthetic space, chronic inflammation, characterized
by proliferation of mesenchymal cells and collagen syn-
thesis, is regularly observed. This chronic inflammation is
morphologically classified as a foreign body reaction and
well known as the periprosthetic capsule [41, 42]. In this
periprosthetic and pericapsular space, silicone migrated
from the shell of the implant can be captured by macro-
phages, which results in activation of these macrophages
[43]. Importantly, oxygen radicals released from this acti-
vated macrophage may result in oxidation of silicone,
leading to the local formation of silica [43]. In experi-
mental studies, it is demonstrated that this results in the
secretion of cytokines, promotion of fibroblast proliferation
and collagen production [44]. In addition, in vivo a sig-
nificant lymphoplasmatic infiltration is observed. This can
lead to continuous stimulation of the immune system,
leading to formation of autoantibodies and the formation of
anti-silicone antibodies [5, 45–47]. It is hypothesized that
the autoimmune/inflammatory process will be reduced by
removing the inducing agent of this process, i.e., the sili-
cone breast implant, [4, 10].
We observed that patients with silicone-related com-
plaints improved after explantation, but patients who have
already developed autoimmune diseases immunosuppres-
sive drugs were additionally needed to induce remission of
the disease. This implies that explantation alone is not
effective for resolution of the autoimmune diseases.
An explanation for this phenomenon could be that prior
to explantation silicone particles have already been
migrated into the periprosthetic tissue, lymph nodes and
other tissues [48, 49]. This implies that the silicone parti-
cles remain present in the body after explantation and that
the autoimmune/inflammatory response continues. This
could also clarify the observation that autoantibodies
remain detectable after explantation.
Reduction in nociceptive signals
Clinical findings in patients with ASIA due to SIIS
resemble the clinical picture of fibromyalgia [50, 51].
Indeed, the type of complaints is more or less identical in
these two diseases. It has been postulated that in
fibromyalgia nociceptive signals (often psychological
trauma) cause the development of symptoms via disturbed
pain processing [52]. Could it be that in patients with ASIA
due to SIIS the breast implant is the nociceptive stimulus
causing the symptoms? Could a disturbed pain signaling
pathway due to the nociceptive stimulus (silicone), in
combination with extensive worrying about the safety of
the breast implant, cause excessive stimulation of neuro-
transmitters in the central nervous system and therefore
cause the systemic complaints [52]? This hypothesis
may—at least partially—explain why patients experience
improvement in symptoms when the silicone breast
implant, and thus the nociceptive stimulus, is explanted and
why improvement in the quality of life is reported. In this
theory, self-evaluation after explantation/after removal of
the nociceptive stimulus should improve, since there is no
longer a reason for extensive worrying. More research
whether the improvement after explantation is due to the
removal of the nociceptive stimulus should be performed.
Practical implications
Silicone-related complaints have been labeled differently
in the past decades (human adjuvant disease, adjuvant
breast disease, ASIA syndrome). Symptoms, however, did
not change during the last 30 years [11]. General practi-
tioners and other specialists should be aware that patients
with silicone breast implants may present with these
symptoms (Table 1). The symptoms, however, are not very
specific. In making the decision that the complaints may be
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related to the silicone breast implants, it is therefore
important to rule out other diseases. For the physician who
advises the patient, it is valuable to inform the patients
what the results of explantation of the breast implant might
be. Importantly, explantation may results in body defor-
mity and impaired body image, which may have a signif-
icant psychological impact [29]. Therefore, patients should
also be informed what alternative reconstruction possibil-
ities are available after explantation. Alternatives can
consist of reconstruction with autologous tissue such as
free flaps (LTP or DIEP flap), lipofilling (with external pre-
expansion) or reconstruction with breast implants filled
with saline or hydrocellulose [28, 33, 53–55]. In this
review, we have found that the effect of reconstruction
after explantation in patients with silicone-related com-
plaints has received extremely little attention up until the
present time. Mamma reconstruction with autologous tis-
sue instead of implants tends to be popular in this category
of patients due to a higher long-term satisfaction, higher
patient’ satisfaction and a higher perception of naturalness
[56]. However, in the current reviewed literature, it is not
yet clear whether autologous tissue is a good alternative
[33]. Reconstruction with a breast implant filled with
hydrocellulose might be another alternative since exposure
to silicone is diminished [15, 28]. However, the evidence
for the use of hydrocellulose-filled implants as a safe
alternative is at present also very limited and importantly,
silicone-related complaints can also occur in patients with
an implant filled with hydrocellulose or saline.
More research on which type of reconstruction could be
used for patients with silicone breast implant-related
complaints should be performed.
Conclusion
The objective of this review was to investigate whether
explantation of silicone breast implants in patients with
silicone-related complaints is useful. We have observed
that in approximately 75 % of the patients with silicone-
related complaints improvement occurs. However, in
patients with silicone breast implants who have developed
an autoimmune disease explantation appears to be suc-
cessful only when explantation is combined with
immunosuppressive therapy. We postulate that both
reduction in the immune response and reduction in noci-
ceptive signals could explain why patients with silicone-
related complaints experience improvement after explan-
tation. Migration of silicone particles into the adjacent
tissue could explain why explanation alone is not suc-
cessful in all patients. Lastly, since very few studies dealt
with the type of reconstruction for the explanted breast, we
strongly suggest that more research should be done
regarding this issue.
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